CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty-two ...

Mammoth Biosciences researchers have developed NanoCas, an ultracompact CRISPR nuclease, demonstrating its ability to perform ...

Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

Scribe Therapeutics hopes to prevent cardiometabolic diseases by targeting underlying causes with CRISPR technology.

Gene editing techniques may eventually allow trisomy to be treated at the cellular level, according to an in vitro ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) will likely be announcing its earnings results before the market opens on ...

The CRISPR-Cas gene scissors offer a wide range of potential applications, from the treatment of genetic diseases to antiviral therapies and diagnostics. However, to safely harness their powers, ...

CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...

A new study links a particular gene to the ancient origins of spoken language in humans. When put in mice, it changed the way ...

USDA Animal and Plant Health Inspection Service (APHIS) announced on January 23, 2025, that it is reinstating its legacy ...

We recently published a list of Shares of 10 Firms Soar on Friday. In this article, we are going to take a look at where ...